Because of the expression of EGFR in non-cancerous tumors, tolerable and controllable target-related toxicities, such as skin rash and diarrhea, have been seen on NSCLC patients in clinical trials [54,55]. Here, EGFR is linked to non-small cell lung carcinoma.